Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rosiglitazone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 12/20 | 1.00 |
| ▸ | RARG | P13631 | 1/20 | 1.00 |
| ▸ | RXRA | P19793 | 1/20 | 1.00 |
| ▸ | PPARA | Q07869 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rosiglitazone SCHEMBL504723 | 1.00 | PPARG (1.00) | PPARGRARGRXRAPPARAKMT2A | |
| Rosiglitazone SCHEMBL5734118 | 1.00 | PPARG (1.00) | PPARGRARGRXRAPPARAKMT2A | |
| Rosiglitazone SCHEMBL122053 | 1.00 | PPARG (1.00) | PPARGRARGRXRAPPARAKMT2A | |
| Rosiglitazone SCHEMBL29376790 | 1.00 | PPARG (1.00) | PPARGRARGRXRAPPARAKMT2A | |
| Rosiglitazone SCHEMBL19469505 | 1.00 | PPARG (1.00) | PPARGRARGRXRAPPARAKMT2A | |
| Rosiglitazone SCHEMBL29757195 | 1.00 | PPARG (1.00) | PPARGRARGRXRAPPARAKMT2A | |
| Rosiglitazone SCHEMBL5556077 | 1.00 | PPARG (1.00) | PPARGRARGRXRAPPARAKMT2A | |
| Rosiglitazone SCHEMBL19023 | 1.00 | PPARG (1.00) | PPARGRARGRXRAPPARAKMT2A | |
| Rosiglitazone SCHEMBL5735765 | 0.99 | PPARG (0.98) | PPARGRARGRXRAPPARAKMT2A | |
| Rosiglitazone SCHEMBL2118157 | 0.99 | PPARG (0.98) | PPARGRARGRXRAPPARAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 358 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-20200187851-A1 | PERIODONTAL DISEASE STRATIFICATION AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2020-06-18 | — | — | US | claimed |
| US-8541456-B2 | Roflumilast for the treatment of diabetes mellitus type 2 | TAKEDA GMBH (DE) | 2013-09-24 | — | — | US | claimed |
| US-20120129817-A1 | COMBINATION TREATMENT FOR DIABETES MELLITUS | NYCOMED GMBH (DE) | 2012-05-24 | — | — | US | claimed |
| US-20110269750-A1 | ROFLUMILAST FOR THE TREATMENT OF DIABETES MELLITUS | NYCOMED GMBH (DE) | 2011-11-03 | — | — | US | claimed |
| EP-2300048-A1 | LIPOCALIN-2 AS A PROGNOSTIC AND DIAGNOSTIC MARKER FOR HEART AND STROKE RISKS | Versitech Limited (CN) | 2011-03-30 | — | — | EP | claimed |
| US-20100179131-A1 | Combination treatment for diabetes mellitus | NYCOMED GMBH (DE) | 2010-07-15 | — | — | US | claimed |
| EP-1474114-B1 | ORAL DOSAGE FORM FOR CONTROLLED DRUG RELEASE | GLAXO GROUP LTD (GB) | 2010-01-20 | — | — | EP | claimed |
| WO-2009132510-A1 | LIPOCALIN-2 AS A PROGNOSTIC AND DIAGNOSTIC MARKER FOR HEART AND STROKE RISKS | VERSITECH LIMITED (CN) | 2009-11-05 | — | — | WO | claimed |
| US-20090274709-A1 | Lipocalin-2 As A Prognostic and Diagnostic Marker For Heart And Stroke Risks | R&C BIOGENIUS LIMITED (CN) | 2009-11-05 | — | — | US | claimed |
| US-20040014791-A1 | Thiazolidinedione derivative and its use as antidiabetic | RECOMGENEX KFT. (HU) | 2004-01-22 | — | — | US | claimed |
| WO-2003099337-A2 | INCLUSION COMPLEXES OF ROSIGLITAZONE | GLAXO GROUP LIMITED (GB) | 2003-12-04 | — | — | WO | claimed |
| EP-1322647-A1 | NOVEL POLYMORPHIC FORMS OF 5-[4-[2-[N-METHYL-N-(2-PYRIDYL)AMINO]ETHOXY]BENZYL]THIAZOLIDINE-2,4-DIONE MALEIC ACID SALT AND PROCESS FOR THEIR PREPARATION | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2003-07-02 | — | — | EP | claimed |
| EP-1315721-A1 | A THIAZOLIDINEDIONE DERIVATIVE AND ITS USE AS ANTIDIABETIC | SMITHKLINE BEECHAM PLC (GB) | 2003-06-04 | — | — | EP | claimed |
| US-6515132-B2 | Reacting 2-chloropyridine with 2-methylaminoethanol, coupling product obtained with 4-fluorobenzaldehyde in a solvent and alkali hydroxide or alkoxide, recovering product, converting into the thiazolidine-2,4-dione and reacting with maleic acid | TORRENT PHARMACEUTICALS, LTD. (IN) | 2003-02-04 | — | — | US | claimed |
| US-20020115866-A1 | Process for the preparation of pyridine derivative | TORRENT PHARMACEUTICALS LTD. | 2002-08-22 | — | — | US | claimed |
| WO-2002051823-A1 | PROCESS FOR THE PREPARATION OF ROSIGLITAZONE MALEATE | TORRENT PHARMACEUTICALS LTD (IN) | 2002-07-04 | — | — | WO | claimed |
| WO-2002026737-A1 | NOVEL POLYMORPHIC FORMS OF 5-[4-[2-[N-METHYL-N-(2-PYRIDYL)AMINO]ETHOXY]BENZYL] THIAZOLIDINE-2,4-DIONE MALEATE AND PROCESS FOR THEIR PREPARATION | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2002-04-04 | — | — | WO | claimed |
| WO-2002020517-A1 | A THIAZOLIDINEDIONE DERIVATIVE AND ITS USE AS ANTIDIABETIC | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-03-14 | — | — | WO | claimed |
| EP-0658161-B1 | SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1999-07-14 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129817-A1 | COMBINATION TREATMENT FOR DIABETES MELLITUS | GPR119, IAPP, MTNR1B | PPARG 79/4885RARG 864/4885RXRA 543/4885 |
| US-20020115866-A1 | Process for the preparation of pyridine derivative | ADH5, ADH1C, ADH1A | PPARG 2337/4885RARG 2767/4885RXRA 3890/4885 |
| US-20110269750-A1 | ROFLUMILAST FOR THE TREATMENT OF DIABETES MELLITUS | PPARD, PPARA, PPARG | PPARG 3/4885RARG 109/4885RXRA 167/4885 |
| US-20100179131-A1 | Combination treatment for diabetes mellitus | GPR119, GLP1R, MTNR1B | PPARG 149/4885RARG 1658/4885RXRA 777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.